SLRX — Salarius Pharmaceuticals Share Price
0.000.00%
Last trade - 00:00- $1.42m
- -$2.84m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.41 | ||
| Price to Tang. Book | 0.41 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -253.31% | ||
| Return on Equity | -193.68% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 3.47 | 5.23 | 1.84 | n/a | n/a | n/a | n/a | -100% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Salarius Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is developing treatments for parties with cancers in need of new treatment options. Its product portfolio includes seclidemstat, an oral novel small molecule inhibitor of the LSD1 enzyme and the Company's lead candidate, which is being studied as a potential treatment for pediatric cancers, sarcomas, and other cancers with limited treatment options, and SP-3164, an oral small molecule protein degrader being developed for the treatment of Non-Hodgkins Lymphoma. SP-3164 is a small molecule protein degrader, and seclidemstat (SP-2577) is a small molecule inhibitor. SP-3164 is a next-generation cereblon-binding molecular glue (MG). SP-2577 is a small-molecule LSD1 inhibitor with a novel scaffold. The molecule was discovered using structure-based computational screening coupled with chemical screening and further optimization with structure-activity relationship studies.
Directors
- William McVicar CHM (63)
- David Arthur PRE (58)
- Mark Rosenblum CFO (67)
- Nadeem Mirza SVP
- Paul Lammers LED (63)
- Bruce Mccreedy DRC (61)
- Tess Burleson IND (54)
- Arnold Hanish IND (73)
- Jonathan Lieber IND (52)
- Last Annual
- December 31st, 2023
- Last Interim
- March 31st, 2024
- Incorporated
- February 26th, 2014
- Public Since
- January 29th, 2015
- No. of Shareholders
- 149
- No. of Employees
- 2
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 597,054
- Address
- 2450 Holcombe Blvd Ste J-608, HOUSTON, 77021-2041
- Web
- https://salariuspharma.com/
- Phone
- +1 6178741821
- Contact
- Maureen McEnroe
- Auditors
- Ernst & Young LLP
Upcoming Events for SLRX
Q2 2024 Salarius Pharmaceuticals Inc Earnings Release
Q3 2024 Salarius Pharmaceuticals Inc Earnings Release
Similar to SLRX
180 Life Sciences
NASDAQ Capital Market
Abeona Therapeutics
NASDAQ Capital Market
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
FAQ
What is the Salarius Pharmaceuticals share price?
As of Today at 23:04 UTC, shares in Salarius Pharmaceuticals are trading at $2.52. This share price information is delayed by 15 minutes.
How has the Salarius Pharmaceuticals share price performed this year?
Shares in Salarius Pharmaceuticals last closed at $2.52 and the price had moved by -77.47% over the past 365 days. In terms of relative price strength the Salarius Pharmaceuticals share price has underperformed the S&P500 Index by -82.07% over the past year.
What are the analyst and broker recommendations for Salarius Pharmaceuticals?
The overall consensus recommendation for Salarius Pharmaceuticals is Hold. You can view the full broker recommendation list by unlocking its StockReport.
What is the Salarius Pharmaceuticals dividend yield?
Salarius Pharmaceuticals does not currently pay a dividend.
Does Salarius Pharmaceuticals pay a dividend?
Salarius Pharmaceuticals does not currently pay a dividend.
When does Salarius Pharmaceuticals next pay dividends?
Salarius Pharmaceuticals does not currently pay a dividend.
How do I buy Salarius Pharmaceuticals shares?
To buy shares in Salarius Pharmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Salarius Pharmaceuticals?
As of the previous close price of $2.52, shares in Salarius Pharmaceuticals had a market capitalisation of $1.50m.
Where are Salarius Pharmaceuticals shares listed?
Here are the trading details for Salarius Pharmaceuticals:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: SLRX
What kind of share is Salarius Pharmaceuticals?
Based on an overall assessment of its quality, value and momentum Salarius Pharmaceuticals is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Salarius Pharmaceuticals share price forecast for 2024?
The analyst consensus target price for shares in Salarius Pharmaceuticals is $26.00. That is 931.75% above the last closing price of $2.52.
Analysts covering Salarius Pharmaceuticals currently have a consensus Earnings Per Share (EPS) forecast of -$214.40 for the next financial year.
What is the trend in the Salarius Pharmaceuticals share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Salarius Pharmaceuticals. Over the past six months, its share price has underperformed the S&P500 Index by -53.9%.
As of the last closing price of $2.52, shares in Salarius Pharmaceuticals were trading -48.16% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Salarius Pharmaceuticals PE Ratio?
The Salarius Pharmaceuticals PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $2.52.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Salarius Pharmaceuticals?
Salarius Pharmaceuticals' management team is headed by:
- William McVicar - CHM
- David Arthur - PRE
- Mark Rosenblum - CFO
- Nadeem Mirza - SVP
- Paul Lammers - LED
- Bruce Mccreedy - DRC
- Tess Burleson - IND
- Arnold Hanish - IND
- Jonathan Lieber - IND